Bright Minds is Unaware of Any Material Changes
At the request of CIRO, Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) has confirmed that the company's management is unaware of any material changes in its operations that could explain the recent increase in market activity. This statement was made in response to unusual trading patterns observed in the company's stock.
The press release, dated October 15, 2024, serves as a formal declaration to investors and regulatory bodies that Bright Minds has not undergone any significant operational changes that would justify the recent market behavior. This type of announcement is often made to ensure transparency and compliance with stock exchange regulations.
Su richiesta di CIRO, Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) ha confermato che la direzione dell'azienda è all'oscuro di eventuali cambiamenti materiali nelle sue operazioni che potrebbero spiegare il recente aumento dell'attività di mercato. Questa dichiarazione è stata rilasciata in risposta a modelli di trading insoliti osservati nelle azioni dell'azienda.
Il comunicato stampa, datato 15 ottobre 2024, funge da dichiarazione formale per gli investitori e gli organismi di regolamentazione che Bright Minds non ha subito alcun cambiamento operativo significativo che giustificherebbe il recente comportamento del mercato. Questo tipo di annuncio viene spesso fatto per garantire trasparenza e conformità alle regolazioni della borsa.
A solicitud de CIRO, Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) ha confirmado que la dirección de la empresa está inconsciente de cualquier cambio material en sus operaciones que pueda explicar el reciente aumento en la actividad del mercado. Esta declaración se realizó en respuesta a patrones de trading inusuales observados en las acciones de la empresa.
El comunicado de prensa, fechado el 15 de octubre de 2024, sirve como una declaración formal para los inversores y organismos reguladores de que Bright Minds no ha sufrido cambios operativos significativos que justifiquen el comportamiento reciente del mercado. Este tipo de anuncio se hace a menudo para garantizar la transparencia y el cumplimiento de las regulaciones de la bolsa.
CIRO의 요청에 따라, Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG)는 회사 경영진이 시장의 최근 활동 증가를 설명할 수 있는 실질적인 변화에 대해 알지 못한다고 확인하였습니다. 이 성명은 회사 주식에서 관찰된 비정상적인 거래 패턴에 대한 응답으로 이루어졌습니다.
2024년 10월 15일자로 발행된 보도자료는 투자자 및 규제 기관에 대한 공식적인 선언으로 Bright Minds가 최근 시장 행동을 정당화할 만한 중요한 운영 변화를 겪지 않았음을 전달합니다. 이러한 유형의 발표는 투명성과 주식 거래소 규정 준수를 보장하기 위해 종종 이루어집니다.
À la demande de CIRO, Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) a confirmé que la direction de l'entreprise n'est pas au courant de changements matériels dans ses opérations qui pourraient expliquer l'augmentation récente de l'activité sur le marché. Cette déclaration a été faite en réponse à des modèles de trading inhabituels observés dans les actions de l'entreprise.
Le communiqué de presse, daté du 15 octobre 2024, sert de déclaration officielle aux investisseurs et aux organismes de réglementation que Bright Minds n'a subi aucun changement opérationnel significatif justifiant le comportement récent du marché. Ce type d'annonce est souvent fait pour garantir la transparence et la conformité aux réglementations boursières.
Auf Anfrage von CIRO hat Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) bestätigt, dass das Management des Unternehmens von wesentlichen Änderungen in seinen Abläufen nichts weiß, die den jüngsten Anstieg der Marktaktivitäten erklären könnten. Diese Erklärung wurde als Reaktion auf ungewöhnliche Handelsmuster beobachtet, die bei den Aktien des Unternehmens registriert wurden.
Die Pressemitteilung vom 15. Oktober 2024 dient als formelle Erklärung für Investoren und Aufsichtsbehörden, dass Bright Minds keine wesentlichen operativen Veränderungen durchlaufen hat, die das jüngste Marktverhalten rechtfertigen würden. Solche Ankündigungen werden oft gemacht, um Transparenz und die Einhaltung von Börsenvorschriften sicherzustellen.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that the Company's management is unaware of any material changes in the Company's operations that would account for the recent increase in market activity.
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first- generation compounds, such as fenfluramine, psilocybin, LSD, and ibogaine.
Investor Contact:
Ian McDonald
CEO and Director
E: ian@brightmindsbio.com
T: (647) 865-8622
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226772
FAQ
Why did Bright Minds Biosciences (DRUG) issue a statement about no material changes on October 15, 2024?
What stock exchanges is Bright Minds Biosciences (DRUG) listed on?
Has there been unusual market activity for Bright Minds Biosciences (DRUG) stock recently?
What is CIRO and why did they request a statement from Bright Minds Biosciences (DRUG)?
